CAR T cells in solid tumors: challenges and opportunities
F Marofi, R Motavalli, VA Safonov… - Stem cell research & …, 2021 - Springer
Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
Metastatic colorectal cancer: mechanisms and emerging therapeutics
AE Shin, FG Giancotti, AK Rustgi - Trends in pharmacological sciences, 2023 - cell.com
Metastatic colorectal cancer (mCRC) remains a lethal disease with an approximately 14% 5-
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …
CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment
M Martinez, EK Moon - Frontiers in immunology, 2019 - frontiersin.org
Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …
Colorectal cancer immunotherapy: options and strategies
NA Johdi, NF Sukor - Frontiers in immunology, 2020 - frontiersin.org
Colorectal cancer is the third most common cancer in the world with increasing incidence
and mortality rates globally. Standard treatments for colorectal cancer have always been …
and mortality rates globally. Standard treatments for colorectal cancer have always been …
Adoptive cellular therapies: the current landscape
MW Rohaan, S Wilgenhof, JBAG Haanen - Virchows Archiv, 2019 - Springer
For many cancer types, the immune system plays an essential role in their development and
growth. Based on these rather novel insights, immunotherapeutic strategies have been …
growth. Based on these rather novel insights, immunotherapeutic strategies have been …
Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions
A Alnefaie, S Albogami, Y Asiri, T Ahmad… - … in bioengineering and …, 2022 - frontiersin.org
Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the
body from pathogenic invaders and can be used as tools to enhance the body's defense …
body from pathogenic invaders and can be used as tools to enhance the body's defense …
Advances in immunotherapy for colorectal cancer: a review
G Golshani, Y Zhang - Therapeutic advances in …, 2020 - journals.sagepub.com
Immunotherapy is a new and exciting modality of cancer treatments. Its role in
gastrointestinal malignancies has been promising, especially in advanced disease …
gastrointestinal malignancies has been promising, especially in advanced disease …
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription
B Xiu, Y Chi, L Liu, W Chi, Q Zhang, J Chen, R Guo… - Molecular cancer, 2019 - Springer
Background The majority of breast cancer patients die of metastasis rather than primary
tumors, whereas the molecular mechanisms orchestrating cancer metastasis remains poorly …
tumors, whereas the molecular mechanisms orchestrating cancer metastasis remains poorly …
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues
Gastrointestinal cancers (GICs) and neuroendocrine tumors (NETs) are often refractory to
therapy after metastasis. Adoptive cell therapy using chimeric antigen receptor (CAR) T …
therapy after metastasis. Adoptive cell therapy using chimeric antigen receptor (CAR) T …